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Rejoinder
William DuMouchel
Many thanks to all of the discussants for their ob-
servations and suggestions and encouraging words.
My response is quite short because I agree with all
of their comments.
Professor Evans points out the importance and
potential difficulty of selecting which set of issues
or adverse event definitions to include in the anal-
ysis. They need to be approximately exchangeable
in terms of prior belief as to their expected asso-
ciations with Treatment and with covariates. Prior
belief refers to your expert opinion before looking
at the data to be analyzed—it would not be appro-
priate to just select issues that are observed to have
high odds ratios with treatment, for example, which
might tend to bias the estimation of variance compo-
nents in the model, making them appear too small.
His suggestion of selecting SMQs that are formed
from terms in a local region of the MedDRA hierar-
chy seems reasonable, or of using other knowledge or
data that seem to point to plausible exchangeabil-
ity. I also agree with Professor Evans on the need for
more experience with how MBLR works with vary-
ing numbers of issues (K) and numbers of covariates
(J) and varying sample sizes. My intuition is that
the model should be robust to a wide range of K
and sample sizes, but that it is probably not a good
idea to allow J to be too large, on the rationale that
collinearity often leads to problems in any regression
model having many covariates. Perhaps J should be
kept in the range of 1 to 5, and I suspect that it
would be a mistake, leading to spurious results, to
think of MBLR as a data mining technique, where
you search for the best 5 covariates out of 50 avail-
able, for example. Better to just use a few prespeci-
fied covariates that have some prior justification for
potential effects or interactions with treatment.
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Professor Berry provides a nice overview of the
inferential and medical difficulties raised by drug
safety issues. Many of these difficulties are beyond
the reach of any mere statistical model, of course.
But in as much as consideration of multiplicities due
to analyses of related medical events and to sub-
group analyses contribute to these problems, per-
haps the MBLR model, or similar approaches using
Bayesian shrinkage, can help researchers see the for-
est through the trees.
Special thanks go to Brad McEvoy and Ram Ti-
wari for their collaborations and discussions during
the later development of MBLR, and now for their
acute comments here. First, they provide an insight-
ful and enlightening discussion of the relationship of
the MBLR model to meta-analysis modeling in gen-
eral, assuming that the data at hand come from mul-
tiple studies. My choice, made for simplicity, was to
treat the Study ID as just another categorical vari-
able like patient age or sex. This should eliminate
certain biases like those due to Simpson’s paradox,
and does allow the treatment effect to vary by Study,
but does not treat Study as an independent random
effect that could potentially interact with all other
covariates. It also makes it difficult to build into the
analysis the fact that patients were independently
randomized within each study, which does not play
much of a role in a Bayesian model, but is an im-
portant aspect of the classical paradigm. McEvoy
and Tiwari define an extended meta-analytic MBLR
model that allows for Study (trial) to be a higher
level of a hierarchical model and fit it to the data
in the paper using the Markov chain Monte Carlo
(MCMC) approach. That model is much more com-
plex, since instead of just 4 prior standard deviations
to estimate, there are (2K + 4) = 24 such hyperpa-
rameters, which would make it impossible to fit us-
ing the simpler methodology of the present paper.
Much more research would be needed to assess the
relative validity and reliability of this more compli-
cated methodology. An alternative approach might
be to fit the current MBLR model separately to the
data from each study, and then using a more tradi-
tional meta-analysis approach as a post-processing
step applied to the coefficients and standard errors
so obtained.
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Drs. McEvoy and Tiwari also focus on the deci-
sion to borrow strength across different issues (AEs),
in that if your prior belief that the issues are ex-
changeable is incorrect, then the shrinkage may not
help and could possibly lead to extraneous variabil-
ity. They point out that careful interpretation is es-
pecially needed when a rare but severe issue is an-
alyzed in conjunction with other more frequent but
less important or interesting issues. This is always
a potential problem whenever a more available vari-
able is being treated as a possible marker for a less
available but more medically severe event or process.
Finally, these discussants used the MCMCmethod
to re-estimate the MBLR coefficient estimates from
the example data and show that they are remark-
ably similar to those based on my Laplace approxi-
mation method. We have replicated this result using
in-house computations, using the same and similar
models.
Once again, many thanks are due to all of the
discussants for their interesting and insightful and
generous comments.
